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Ca2+-sensing receptors (CaSRs) play a central role in regulating extracellular calcium
concentration ([Ca2+]o) homeostasis and many (patho)physiological processes in
multiple organs. This regulation is orchestrated by a cooperative response to extracellular
stimuli such as small changes in Ca2+, Mg2+, amino acids, and other ligands.
In addition, CaSR is a pleiotropic receptor regulating several intracellular signaling
pathways, including calcium mobilization and intracellular calcium oscillation. Nearly
200 mutations and polymorphisms have been found in CaSR in relation to a variety
of human disorders associated with abnormal Ca2+ homeostasis. In this review, we
summarize efforts directed at identifying binding sites for calcium and amino acids.
Both homotropic cooperativity among multiple calcium binding sites and heterotropic
cooperativity between calcium and amino acid were revealed using computational
modeling, predictions, and site-directed mutagenesis coupled with functional assays.
The hinge region of the bilobed Venus flytrap (VFT) domain of CaSR plays a pivotal role
in coordinating multiple extracellular stimuli, leading to cooperative responses from the
receptor. We further highlight the extensive number of disease-associated mutations
that have also been shown to affect CaSR’s cooperative action via several types of
mechanisms. These results provide insights into the molecular bases of the structure
and functional cooperativity of this receptor and other members of family C of the G
protein-coupled receptors (cGPCRs) in health and disease states, and may assist in the
prospective development of novel receptor-based therapeutics.
Keywords: calcium sensing receptor, cooperativity, amino acids, structure, trafficking, disease mutations
INTRODUCTION
In 1883, Sydney Ringer serendipitously discovered Ca2+ to be essential for the contraction of
isolated hearts (Ringer, 1883). After the mid-twentieth century, research on Ca2+ has grown at an
exponential rate, and Ca2+ is now considered as a universal signal carrier for biological information
(Krebs andMichalak, 2007). Ca2+ controls life and death, as it modulates the process of fertilization
as well as apoptosis. Ca2+ was primarily considered as a crucial secondary messenger via rapidly
and efficiently regulated changes in intracellular calcium levels, and modulated extensive molecular
signaling components through calcium channels, exchangers along with pumps. The discovery
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of the calcium sensing receptor (CaSR) defined an additional
role of extracellular Ca2+ as a first messenger (Smajilovic and
Tfelt-Hansen, 2007). It is known that serum Ca2+ concentration
can regulate the secretion of parathyroid hormone (PTH) and,
therefore, research was pursued to investigate how this process
is accomplished. In 1993, Dr. Edward M. Brown cloned CaSR,
which is primarily responsible for this type of regulation, from
bovine parathyroid gland (Brown et al., 1993). The previously
observed cytosolic Ca2+ changes in parathyroid cells, as well
as in other in vitro expression systems, were triggered by
changes in serum Ca2+ concentration and have been largely
proven to be mediated by the CaSR (Nemeth and Scarpa, 1987;
Muff et al., 1988). In addition to the key tissues involved in
extracellular Ca2+ and Mg2+ homeostasis (e.g., parathyroid,
thyroid, kidney, bone), CaSR has also been reported to be
present in diverse other, non-homeostatic tissues (e.g., brain,
skin, etc.) (Lundgren et al., 1994; Hebert, 1996; Cima et al.,
1997; Hinson et al., 1997; Cheng et al., 1998; Kovacs et al.,
1998; Chattopadhyay et al., 1999; Brown and MacLeod, 2001;
Buchan et al., 2001; Mathias et al., 2001; Hofer and Brown,
2003; Chang and Shoback, 2004; Fudge and Kovacs, 2004; Hofer
et al., 2004). To date, extracellular Ca2+ has been shown to
be a first messenger via CaSR and 14 other family cGPCRs,
including metabotropic glutamate receptors (mGluRs) and γ-
aminobutyric acid (GABA)B receptors. As shown in Figure 1,
high [Ca2+]o triggers multiple CaSR-regulated intracellular
signaling pathways, including Gq/11 signaling, Gi/osignaling, Gs
signaling, extracellular signal-regulated kinases 1 and 2 (ERK1/2)
signaling, and intracellular calcium mobilization.
CaSR is comprised of 1078 amino acids, and is encoded by
exons 2–7 to encompass a 19 amino acids (AA) N-terminal
signal peptide, a ∼600 AA extracellular domain (ECD), a
cysteine rich domain (CRD), a ∼250 AA 7-transmembrane
(7TM) domain, and the ∼216 AA intracellular domain (ICD)
(Pollak et al., 1993; Chikatsu et al., 2000; Hendy et al., 2013).
The ECD of CaSR not only plays crucial roles in the sensing
of nutrients, such as Ca2+, L-Phe and polypeptides, allowing
ligands to modulate CaSR cooperatively, but is also essential
for the dimerization of the receptor (Ray et al., 1999; Zhang
et al., 2014b). Binding of Ca2+ and other CaSR ligands to the
ECD is thought to produce conformational changes in the 7TM
domain, introducing alterations in intracellular loops and the C-
terminal domain, which further trigger the downstream signaling
pathways (Brown and MacLeod, 2001). The intracellular C-
terminal domain (residues 863–1078) is quite diverse among
species. It participates in controlling the CaSR signaling and its
cooperativity, modulating receptor trafficking, expression and
desensitization (Gama and Breitwieser, 1998; Bai, 2004; Ward,
2004; Huang et al., 2006).
A unique characteristic of CaSR is the high cooperativity of
Ca2+ dependent activation, which tightly controls the secretion
of parathyroid hormone when the receptor is exposed to
serum Ca2+ concentrations within its responsive range and also
regulates the delicate Ca2+ homeostasis within the body as a
whole (Brown et al., 1993). Functional cooperativity of CaSR (i.e.,
based on biological activity determined using functional assays),
particularly the functional positive homotropic cooperative
response to extracellular calcium, is essential for the receptor’s
ability to respond over a narrow physiological range of [Ca2+]o
(1.1–1.3mM) (Breitwieser, 2006). CaSR has an estimated Hill
coefficient of 3–4 for its regulation of biological processes,
such as activating intracellular Ca2+ signaling, inhibiting PTH
release in parathyroid cells (Figure 1) and stimulating calcitonin
secretion in C-cells (Walter et al., 2013). Other extracellular
mineral cations, such as Mg2+, and amino acids, are able to
function as agonists and co-agonists to regulate/potentiate the
Ca2+-induced activation of the CaSR. L-amino acids, especially
aromatics, at physiological conditions potentiate the Ca2+–
elicited activation of the CaSR by altering the EC50 values
for extracellular calcium evoked intracellular calcium responses
via positive heterotropic functional cooperativity (Conigrave
et al., 2000; Francesconi and Duvoisin, 2004; Wang et al.,
2006). This capacity of CaSRs to integrate both divalent cations
and other extracellular stimuli, such as amino acids (Vetter
and Lohse, 2002), is a feature shared by other cGPCRs (Wise
et al., 1999; Galvez et al., 2000; Gether, 2000; Oldham and
Hamm, 2008; Rosenbaum et al., 2009). In this paper, we will
review the major discoveries and approaches that have been
taken in uncovering the molecular basis of the cooperative
responses of CaSR and its impact in understanding molecular
bases of diseases (Zhang et al., 2014b). Key determinants
contributing to the functional cooperativity of CaSR including
the calcium and ligand binding sites, and the connectivity
between distant sites on the ECD domain as well as protein
expression at themembrane surface and intracellular domain will
be discussed.
CHALLENGES
To date, how Ca2+, Mg2+, and amino acids cooperatively
modulate intracellular Ca2+ signaling is a long-standing
unanswered question mainly due to the lack of a determined
CaSR structure. Like other cGPCRs, CaSR functions as a dimer
(Bai et al., 1998a, 1999; Pace et al., 1999; Kunishima et al., 2000;
Zhang et al., 2001; Bai, 2004; Suzuki et al., 2004) with a very
long N-terminus that is predicted to fold into a bilobed ECD
(Brown et al., 1993; Hebert and Brown, 1995; Pearce et al.,
1996; Hinson et al., 1997; Hofer and Brown, 2003; Hu and
Spiegel, 2003; Jingami et al., 2003; Quinn et al., 2004). The ECD
has been shown to play an important role in the cooperative
responses of the receptor to changes of [Ca2+]o, amino acids,
metabolites, and neurotransmitters (Bai, 1999, 2004; Conigrave
et al., 2002; Zhang et al., 2002; Chang and Shoback, 2004;
Conigrave and Lok, 2004; Mun et al., 2004). Determination of
the X-ray structure of the ECD of CaSR is largely hampered by
difficulty in crystallization due to heterogeneous and extensive
glycosylation (11 potential N-glycosylation sites) and challenges
associated with membrane proteins (Yang et al., 2005). Further,
Ca2+ and ligand-binding sites with weak binding affinities and
rapid off rates are often not occupied in a determined X-ray
structure. For example, no bound Ca2+ has been observed in
over 30 X-ray structures of the ECD of mGluRs (Kunishima et al.,
2000; Tsuchiya et al., 2002; Jiang et al., 2010; Zhang et al., 2014a),
Frontiers in Physiology | www.frontiersin.org 2 September 2016 | Volume 7 | Article 441
Zhang et al. CaSR Mediated Cooperative Ca2+ Signaling
FIGURE 1 | Various types of agonists, including cations, peptides, amino acids, antibiotics, etc., can act on the extracellular calcium-sensing receptor
(CaSR) to generate a complex intracellular signaling network. CaSR is also a pleiotropic receptor in its regulation of four G protein-mediated intracellular
signaling pathways (Gq/11, Gi/o, Gs, and G12/13 ). The correlations and crosstalk among different signaling cascades contribute the cooperative responses of
intracellular calcium responses as well as parathyroid hormone (PTH) secretion (left) and intracellular calcium responses (right) to extracellular calcium. Bottom left: The
sigmoidal relationship between calcium concentration in blood and PTH level in serum is demonstrated. Higher Ca2+ concentration is required for normal level of PTH
in patients with familial hypocalciuric hypercalcemia (FHH) or patients with Neonatal Severe Primary Hyperparathyroidism (NSHPT), as the response curve shifts to the
right; on the other hand, lower Ca2+ concentration than normal is enough to trigger PTH secretion in patients with autosomal dominant hypocalcemia (ADH). PM,
Plasma membrane; ER, Endoplasmic reticulum; AA, arachidonic acid; AC, adenylate cyclase; cAMP, cyclic AMP; DAG, diacylglycerol; ERK1/2,
extracellular-signal-regulated kinase; Gs, Gi/o,G12/13, and Gq/11, subunits of the s-, i-, 12/13, and q-type alpha subunit of heterotrimeric G proteins, respectively;
Gβγ, G beta and gamma complex; IP3, inositol-1,4,5-trisphosphate; IP3R, inositol-1,4,5-trisphosphate receptor; PLC, phospholipase C; PI(4,5)P2,
phoshatidylinositol-4,5-bisphosphate; RhoA, Ras homolog gene family, member A.
despite the clear modulatory effect of [Ca2+]o on this receptor.
Furthermore, additional challenges result from the lack of direct
binding assays for weak Ca2+-binding, amino acid-binding (Kd
∼mM) and limitations in obtaining purified membrane proteins
with native conformations (Nagar et al., 1996; Hu and Spiegel,
2003; Magno et al., 2011). The quantification of functional
cooperativity with binding cooperativity and visualization of
the molecular connectivity in tuning cooperativity requires
innovative approaches.
MODELING STRUCTURES OF THE CaSR
Several regions of the CaSR and mGluRs are highly homologous,
providing the basis for molecular modeling of the structure
of CaSR under various conditions based on the determined
crystal structures of mGluRs with and without ligands or
agonists/antagonists (Bai, 2004; Hu and Spiegel, 2007; Huang
Y. et al., 2007). Various mGluR structures have indicated that
agonist binding induces a rearrangement of the dimeric VFT
by bringing the two monomers closer together owing to pulling
the lower lobes inwards upon the change toward the closed
state. This is further evidenced by the addition of gadolinium,
which is found to likely stabilize the active form of mGluR1
(Tsuchiya et al., 2002). Recent crystal structures of various
mGluRs have been solved that shed light on several possible
sequential activation events. Orthosteric ligands bind to the VFT
in the dimer, stabilizing the closed conformation to induce an
activation signal to the transmembrane domain by the CRD,
which then activates G protein-regulated signaling pathways
(Kunishima et al., 2000; Jingami et al., 2003; Muto et al., 2007;
Wu et al., 2014).
Figure 2 shows three modeled structures of the ECD of CaSR
in different conformational states based on the crystal structure
of mGluRs. The ECD of CaSR possesses a featured bilobed VFT
structure similar to mGluRs and bacterial periplasmic binding
proteins (O’Hara et al., 1993; Ray et al., 1999; Reyes-Cruz
et al., 2001). These modeled structures of CaSR derived from
several crystal structures of mGluR1 provide molecular views
of large conformational variances among different states and
therefore provide a potential functional mechanism of CaSR
and by extension, of other cGPCRs. The VFT region alternates
between closed and open states, determined by the presence of
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a ligand (e.g., glutamate for mGluR1 or Ca2+ for CaSR), which
then causes the signal to be relayed to the 7TM domain. As
cGPCRs are only functional as dimers, the dimerization of CaSR
is likely to be driven by the hydrophobic interactions between
the monomers along the dimer interface. CaSR and mGluR
protomers are also covalently linked by several disulfide bridges
between the two monomers. A ligand induced rearrangement
of the dimeric VFT brings the two monomers closer together
by pulling the lower lobes inwards upon the change toward
the closed state. Similar to mGluR, the ligand was proposed
to interact with both lobes of the VFT to stabilize the closed
form by providing additional points of contact between the lobes
(Kunishima et al., 2000).
The homology models of the CaSR 7TM domain was built
based on the crystal structure of bovine rhodopsin by several
independent research groups (Petrel et al., 2003; Miedlich et al.,
2004; Hu et al., 2006; Bu et al., 2008). Miedlich et al. docked
the CaSR with the antagonist, NPS 2143, and the calcimimetic,
NPS R-568, to the derived 7TM domain model structure and
reported a shared pocket composed of residues F668, F684
and E837 (Miedlich et al., 2004). The evidence that there are
additional Ca2+-binding sites located at the 7TM domain of the
CaSR (7TM) have been provided by different independent groups
(Hauache et al., 2000; Hu et al., 2002, 2005). The ECD portion
of CaSR, including the CRD linker, has a 30–35% sequence
similarity across all mGluRs, while the linker alone has 65–70%
similarity (Bai, 2004). Together with a recent determination of
structure of the ECD domain of mGluR3 with the cysteine-rich
domain and the transmembrane domain of mGluR1 makes it
possible to model the full length CaSR shown in Figures 2C,D.
Due to high sequence homology, the modeled transmembrane
structure provides more structural information than previous
modeled 7TM domains based on the crystal structure of bovine
rhodopsin (Petrel et al., 2003;Miedlich et al., 2004; Hu et al., 2006;
Bu et al., 2008). These modeling and structural studies, therefore,
provide important insights into the large conformational changes
induced by agonist binding to both mGluR and CaSR. For
instance, the ECD is changed from an open status to a closed
form, although the calcium binding sites and amino acid binding
sites remain elusive due to their weak binding affinities.
IDENTIFICATION OF CA2+ BINDING SITES
IN THE ECD AND THEIR HOMOTROPIC
COOPERATIVITY
Since the ECD is responsible for the main binding activity,
researchers turned to identifying the binding regions for Ca2+
and amino acids based on studies from homology modeling,
mutational studies and the effect of disease related mutations
(Silve et al., 2005). To overcome the challenges involved in
identifications of calcium binding sites with weak binding affinity
of membrane proteins, Huang et al. developed a computational
algorithm to be used for the prediction of potential Ca2+ binding
pockets based on a statistical analysis of multiple calcium binding
proteins (Huang Y. et al., 2007; Kirberger et al., 2008; Huang
et al., 2009; Wang et al., 2009, 2010; Zhao et al., 2012). Shown
in Figure 3, five potential Ca2+-binding sites were predicted in
each monomer of the ECD of the homologous model of CaSR.
Site 1 (S147, S170, D190, Y218, and E297) is located within the
hinge region between the two lobes of the ECD (Kubo et al.,
1998; Silve et al., 2005; Huang Y. et al., 2007). It is interesting to
note that E297, S147, and S170 were reported to be important
for sensing Ca2+ and/or amino acids (Bai et al., 1999; Mun
et al., 2005; Silve et al., 2005). Recently, a novel Ca2+-binding
site in the similar hinge region adjacent to the reported L-Glu
binding site in mGluR1 was found to synergistically activate the
receptor with L-Glu, and enhance the activity of the mGluR1
orthosteric and allosteric ligands (Jiang et al., 2010, 2014). This
same phenomenon may also be applicable to other type of
cGPCRs.
Since the initial prediction, several complementary
approaches have been used to provide important insights
into how CaSR functions and the behavior of the receptor at
the molecular level. First, functional cooperativity contributed
by each Ca2+-binding site was determined by site-directed
mutagenesis and monitoring intracellular Ca2+ oscillations, IP
production and ERK1/2 activation in living cells. We reported
that the predicted Ca2+-binding site 1 within the hinge region
of the ECD of CaSR and its interaction with other Ca2+-binding
sites within the ECD is essential in tuning functional positive
homotropic cooperativity of CaSR caused by changes in [Ca2+]o.
Furthermore, molecular dynamic simulations indicated that
there is molecular connectivity among the other predicted
Ca2+-binding sites with site 1 and that the VFT hinge domain
plays a central role in functional cooperativity (Zhang et al.,
2014a). These results from various functional studies suggest that
cooperative binding of Ca2+ at multiple predicted Ca2+-binding
sites of the CaSR likely maximizes its capacity to respond over
a narrow physiological range of [Ca2+]o independent of amino
acids or other agonists (Bai et al., 1998a; Zhang et al., 2001; Bai,
2004; Figure 2)
The direct binding of Ca2+ to the other predicted Ca2+-
binding sites in the ECD of CaSR and related binding
cooperativity has been probed by using several methods. Ca2+
binding capabilities of predicted Ca2+-binding Site 3 (residues
E224, E228, E229, E 231 E232), and Site 5, which is formed by
contiguous Ca2+ binding residues (residues E378, E379, T396,
D398, E399), were verified using a grafting approach (Huang
Y. et al., 2007). By grafting peptide sequences composed of key
predicted Ca2+ ligand binding residues separated by flexible
linkers into a non-Ca2+-binding protein, site specific Ca2+
binding capability was determined using a Tb3+-sensitized FRET
assay. Huang et al. also applied this approach to probe Ca2+
binding at three additional Ca2+ binding sites and potential
binding cooperativity. Three major subdomains of the CaSR
containing various numbers of predicted Ca2+ binding sites
were expressed and purified. Their Ca2+-binding capabilities
were examined using mutagenesis studies combined with various
spectroscopic studies utilizing 8-anilino-1-naphthalenesulfonic
acid (ANS) fluorescence, intrinsic tryptophan fluorescence
spectra and nuclear magnetic resonance (NMR) (Huang et al.,
2009). It was striking to observe that subdomain 1 with three
binding sites (including sites 1, 2, and 3) exhibited a large
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FIGURE 2 | Homology models of the CaSR ECD. (A) Structural alignment of the mGluR1 holo form (cyan; PDB ID 1EWK, mGluR1 with glutamate) with the
modeled structure of CaSR (red). (B) Structural alignment of mGluR1 apo form I (cyan, PDB ID 1EWV) with the modeled structure of CaSR (yellow). (C) Structural
alignment of mGluR1 apo form II (cyan, PDB ID 1EWT) with the modeled structure of CaSR (green). (D) Homology model of the full CaSR structure. The ECD is based
on the crystal structure of CaSR, the cysteine rich domain modeled from mGluR3 (PDB ID 2E4U), and the 7TM domain is modeled from mGluR1 with a ligand (PDB ID
4OR2). The C-terminal of CaSR can interact with protein kinases, ubiquitin ligase, CaM, etc. The region including residues from 868 to 901 is predicted to be CaM
binding site. Mutations on the CaM binding site compromise the stability of surface expressed CaSR (Huang et al., 2010). PM: Plasma Membrane.
Ca2+ dependent conformational change. A binding process
with strong and weak Ca2+-binding affinities has been clearly
unveiled for subdomain 1 by both fluorescence and NMR studies.
These studies not only confirmed the existence of multiple Ca2+
binding sites, but also revealed that the molecular connectivity
among multiple metal binding sites is essential for a highly
cooperative functional activity (Figure 2).
The complex glycosylated and high mannose CaSR ECD
(residues 20–612) were purified from HEK293S and its mutant
cell line (Zhang et al., 2014c). Using various spectroscopic
methods, it was shown that both form the ECD bound to Ca2+
with aKd of 3.0–5.0mM. The local conformational changes of the
proteins induced by their interactions with Ca2+ were visualized
by NMR with specific 15N Phe-labeled forms of the ECD. These
studies also suggest that glycosylation does not affect calcium
binding properties.
IDENTIFICATION OF AMINO ACID
BINDING SITE AND HETEROTROPIC
FUNCTIONAL ACTIVITY
The extracellular calcium induced activation of CaSR is
potentiated by L-amino acids to maintain the whole body
Ca2+ homeostasis, making the receptor a multimodal and
multimetabolic sensor (Francesconi and Duvoisin, 2004;
Breitwieser, 2006; Conigrave et al., 2007a). Under physiological
conditions, L-amino acids, especially aromatic amino acids
(e.g., L-Phe, L-Trp), as well as short aliphatic and small polar
amino acids, potentiate the extracellular calcium triggered CaSR
activity by altering the EC50 values required for Ca2+-evoked
intracellular calcium responses and its functional cooperativity.
For example, the EC50 for Ca2+ decreased from 4.2 ± 0.2 to
2.5 ± 0.1mM in the presence of L-Phe (Conigrave et al., 2000,
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FIGURE 3 | Molecular connectivity and heterotrophic cooperativity. (A) The correlated motions between calcium binding site 1 and the other calcium binding
sites, designated by roman numbers (I∼V), are mapped onto the CaSR ECD models. The correlation map and parameters for molecular dynamics simulation can be
found in the paper (Zhang et al., 2014a). Bottom: The hetero-communication between Ca2+ and an amino acid functions as a dual switch that enhances the function
of CaSR by positively impacting multiple Ca2+-binding sites within the ECD. Red sphere: Ca2+. Two headed arrow: both ligands can affect the binding of the other,
therefore, the downstream signaling pathways. (B) The intracellular Ca2+ responses of HEK293 cells transiently overexpressing an active mutation or an inactive
mutation. Inset: Representative response of WT CaSR to the changes of extracellular Ca2+ in the absence or presence of L-Phe, showing homotropic, and
heterotropic cooperativity. Some disease mutations can interrupt the homotropic cooperativity shown as intracellular calcium responses to changes in the extracellular
calcium concentration as well as the heterotropic cooperativity in the presence of allosteric modulators (e.g., L-Phe). Open circles: in the absence of L-Phe; Closed
circles: in the presence of 5mM L-Phe. Yellow “pacman”: Ca2+ binding sites in an active receptor; Blue “pacman”: Ca2+ binding sites in an inactive receptor. Pink
stars: gain-of-function mutations in the hinge region. Black stars: loss-of-function mutations in the hinge region. Two headed arrows with solid lines: enhanced
correlation motions between different Ca2+ binding sites. Two headed arrows with dash lines: impaired correlation motions.
2007a; Wang et al., 2006). At the threshold level of extracellular
Ca2+ concentration, L-amino acids induced slow intracellular
Ca2+ oscillations with a frequency at around 1–2 peaks/min
(Breitwieser, 2006). In aggregate, the levels of amino acids in
human serum in the fed state are close to those activating the
CaSR in vitro (Conigrave et al., 2000, 2007b) and can further
enhance functional cooperativity via positive heterotropic
cooperativity. The CaSR in cells within the lumen of the
gastrointestinal (GI) tract are also activated by L-Phe and other
amino acids, which have been long recognized as activators of
key digestive processes. Thus, the CaSR enables the GI tract to
monitor events relevant to both mineral ion and protein/amino
acid metabolism, in addition to its sensing capability in blood
and related extracellular fluids (Conigrave et al., 2000; Wang
et al., 2006; Broadhead et al., 2011; Liou et al., 2011). Distinctive
signaling pathways elicited by amino acids compared with Ca2+
have been demonstrated in quite a few studies (Breitwieser, 2006;
Broadhead et al., 2011). Ca2+ activates CaSR though activation
of the heterotrimeric GTP binding protein Gq, causing the
generation of Ins(1,4,5)P3 (IP3), which binds to the IP3 receptor
on the ER, releasing stored Ca2+. On the other hand, L-Phe in
the presence of Ca2+ induces coupling to heterotrimeric GTP
binding protein G12/13, leading to the activation of RhoA via
filamin A.
Some potential L-Phe binding site residues in the CaSR were
identified based on the conserved amino acid residues involved
in the binding of glutamate to mGluRs (Zhang et al., 2002). Their
studies demonstrated that mutating three adjacent Ser (S169,
S170, S171) to Ala eliminated L-Phe potentiated receptor activity
measured by [Ca2+]i mobilization using a fluorescence-based cell
population assay. Meanwhile, studies from Mun et al. showed
the binding site for amino acids was within the VFT domain
of CaSR by utilizing CaSR-mGluR chimeric receptor constructs.
The receptor lacking the ECD exhibited impaired response to
L-amino acids (Mun et al., 2004). The same group showed that
two residues, Thr145 and Ser170, could be crucial for sensing
L-amino acids, using mutagenesis and fluorimetry studies (Mun
et al., 2005).
Recently, an L-Phe binding site adjacent to the previously
predicted calcium-binding site 1 based on computational
docking results was reported. The potential L-Phe-binding site
is composed of residues Leu51, Thr145, Ser170, Tyr218, and
Ser272. The residue Tyr218 is involved in both Ca2+ and
Phe binding. Extensive mutational studies using both single
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cell imaging and fluorimetric assays identified the importance
of L-Phe-binding pocket for positive heterotropic cooperativity
between extracellular Ca2+ and L-Phe in eliciting CaSR-mediated
Ca2+ signaling (Zhang et al., 2014a). The frequency of sinusoidal
intracellular Ca2+ oscillations in CaSR transfected HEK293 cells
not only depend on the extracellular Ca2+, but also affected by
the binding of allosteric modulators. For example, the binding of
CaSR with Ca2+ alone produces a intracellular Ca2+ oscillations
frequency (1.5/min at room temperature) which is different
than those produced by Ca2+ with L-amino acid (e.g., L-
Phe) (2.2/min) (Breitwieser, 2006; Zhang et al., 2014b). This
change in frequency is extremely important for the role of
CaSR signal transduction in the many different tissue and organ
environments in which it is present. For instance, the Ca2+
oscillations in parathyroid, kidney, intestine and bone are tightly
related to maintenance of Ca2+ homeostasis while the Ca2+
signals are processed differently in many epithelial cells and the
nervous system (Riccardi, 2002; Breitwieser, 2006).
The hetero-communication between Ca2+ and an amino acid
functions as a dual switch that globally enhances functional
positive homotropic cooperative activation of CaSR in response
to Ca2+ signaling by positively impacting multiple Ca2+-binding
sites within the ECD (Figure 3; Zhang et al., 2014a). A direct
interaction between the CaSR ECD and L-Phe was finally
reported using saturation transfer difference NMR approaches
with a determined binding affinity of ∼10mM in the absence
of Ca2+ (Zhang et al., 2014c). The study further demonstrated
that L-Phe increases the binding affinity of the CaSR ECD for
Ca2+. Thus, dual binding of calcium and amino acids at the hinge
regions of the bilobed VFTD of the CaSR leads to activation of the
receptor with highly cooperative responses to the changes in the
extracellular concentrations of these agonists (Figure 4).
MOLECULAR BASIS OF DISEASE
RELATED CASR MUTATIONS
More than 200 mutations of the CaSR that lead to the disorders
of Ca2+ homeostasis have been identified (http://www.casrdb.
mcgill.ca/) (Hendy et al., 2009). Mutations of CaSR may inhibit
receptor activity, lead to an over activation of the receptor,
or markedly impair the receptor’s structure. The majority of
these disease-associated mutations are missense mutations, with
a single amino acid substituted, often from one base pair change.
Amino acids insertion, deletion, open reading frame shift, and
splice-site mutations have also been reported (Hendy et al., 2009).
The diseases associated with inactivate receptors include cases of
Familial Hypocalciuric Hypercalcemia (FHH) (Ward et al., 2006)
and Neonatal Severe Hyperparathyroidism (NSHPT) (Thakker,
2004) while the disorders associated with the CaSR activating
mutations include Autosomal Dominant Hypocalcemia (ADH)
(Hendy et al., 2000) and Bartter syndrome type V (Watanabe
et al., 2002).
Below is the summarized four types of disease mutations
based on their distinct mechanisms of action. Type I and type
II mutations alter the CaSR’s function, especially EC50 or Hill
FIGURE 4 | Schematic representation of the mechanisms underlying
the effects of the mutations on the CaSR and the modulation of
receptor activity by extracellular Ca2+ and L-Phe. Ca2+ and L-Phe
modulate the activity as well as the cooperativity of CaSR (the color changes
of the receptor from ivory to red indicate an increase in functional activity).
Elevating [Ca2+]o, e.g., to 3.0mM, is proposed to change the basal WT CaSR
status into an active form in a positive homotropic cooperative manner and
further trigger intracellular Ca2+ oscillations. L-Phe binds to the hinge region
between lobe 1 and lobe 2, modulating the receptor together with Ca2+ in a
positive heterotropic cooperative way. This could potentiate conversion of the
receptor to a “fully active” form associated with a higher frequency of
intracellular Ca2+ oscillations and a left-shifted EC50. Loss-of-function CaSR
mutants (indicated by ivory color) could cause a disruption of the cooperativity
among the various Ca2+-binding sites as shown by impaired correlation
motions (dashed arrows). The impaired receptor function and the cross-talk
between Ca2+-binding sites can be at least be partially rescued for some
mutants by L-Phe (e.g., P221Q). However, if the mutation interferes with the
interaction between CaSR and L-Phe, the function of the receptor may not be
fully recovered (e.g., L173P). CaSR gain-of-function mutants (left) exhibit
enhanced correlated motions (double line arrows) and their activity is not
further potentiated by L-Phe, potentially due to a ceiling effect. LB1(2): Lobe 1
or lobe 2 in the VFT domain of CaSR.
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number without altering surface expression or trafficking. Type
III and type IV mutations largely affect degree of cooperativity
via altering surface expression and trafficking of the protein to
the plasma surface (Figure 5, Table 1).
The first type of mutational effect, type I, is via direct
alterations in key calcium and ligand binding capability at
or in close proximity to the predicted ligand binding sites
in the ECD (Figure 5). Hannan et al. found that more than
50% of their newly identified CaSR mutations in patients
with FHH, NSHPT, and ADH are within the ECD of the
receptor (Hannan et al., 2012). Analysis using the homology
modeled structure of the CaSR further revealed that >50% of
these missense substitutions are located within 10 Å of one
or more proposed calcium-binding sites, indicating that the
bilobed VFT domain plays a pivotal role in interacting with
Ca2+ and regulating the function of CaSR (Hannan et al.,
2012). Intriguingly, more than half of the mutations near
Ca2+-binding sites are situated close to Site 1, suggesting the
importance of the VFT domain cleft. The molecular connectivity
between Site 1 and rest of the calcium-binding sites can possibly
facilitate the positive cooperativity of the CaSR (Zhang et al.,
2014d).
Through Ca2+ binding site modeling and mutational studies,
several key residues for the predicted Ca2+ binding sites in the
hinge region of the VFT domain have been identified (Deng et al.,
2006; Huang Y. et al., 2007; Huang et al., 2009). Amongst them,
more than half of the ECD mutations are near the proposed
Ca2+ binding sites, and a few of them are found directly in
the potential binding site residues. One ADH mutation (E297D)
and several FHH mutations (Y218S, Y218C, and E297K) are
within Ca2+ binding site 1. The FHHmutation D215G is located
in Ca2+ binding site 2 while two ADH mutations E228Q and
E228K are in Site 3. The Ca2+ binding Site 4 embraces residues
involved in a carcinoma-associatedmutation E350V and anADH
mutation E354A. Mutations on these key binding residues leads
to a decrease of the EC50 of Ca2+ in ADH in order to produce
PTH, and an increase of EC50 in FHH or NSHPT. This can also
lead to an alteration of binding cooperativity between the other
Ca2+ binding sites, allowing them to bind more or less effectively
as indicated by changes in the Hill number. Several studies have
FIGURE 5 | Summary of four types of disease mutations. The CaSR trafficking, expression and surface stabilization contribute to its functional cooperativity. Type
I disease associated mutations directly alter key calcium and ligand binding capability at or in close proximity of the predicted ligand binding sites in the ECD. Type II
mutations alter CaSR function especially EC50 or Hill number without altering surface expression or trafficking, but affect the molecular connectivity between different
ligand binding sites. Type III mutations disrupt the cooperativity via interfering with the receptor cell surface expression and Type IV mutations largely affect potency of
cooperativity by altering trafficking and protein stability via interaction with proteins binding to the CaSR intracellular C-tail.
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TABLE 1 | Summarized molecular basis of disease related CaSR mutations.
Mutation Function on CaSR Examples References
types
Type I Mutations directly affecting key Ca2+ and ligand binding
residues or in close proximity of binding pocket. Leads to a
loss-of- or gain-of-function of CaSR.
E297K, E297D, Y218S, Y218C, R227L,
E191K, E228Q, E228K, E350V, E354A,
D215G, etc.
Pearce et al., 1996; Silve et al., 2005; Deng et al.,
2006; Huang Y. et al., 2007; Huang et al., 2009;
Hannan et al., 2012; Zhang et al., 2014d
Type II Mutations disrupting the molecular connectivity embedded
into the hinge region of the ECD between other proposed
Ca2+ sites, without effect on surface expression or
intracellular trafficking.
L173F, L173P, P221Q, and P221L. Felderbauer et al., 2006; Zhang et al., 2014b
Type III Mutations leading to a decreased or increased potency of
cooperativity by altering its cell surface expression. Have
lower expression or overexpression on the cell surface of
CaSR leads to a change in Ca2+-sensing capabilities.
P39A, G143E, L174R, C582Y, R638L,
S657Y, P748R, G778D, E297K, C395R,
A804D, P55L, S137P, R185Q, D215R,
G553R, R795W, V817I, P798T, S657Y,
G670E, R680H, M734R, etc.
Bai et al., 1998a; Fan et al., 1998; Zhang et al.,
2001; Christopoulos and Kenakin, 2002; Casadó
et al., 2007; Huang and Breitwieser, 2007; White
et al., 2009; Leach et al., 2013
Type IV Mutations which effect cooperativity of CaSR by hampering
its intracellular trafficking capabilities and protein stability via
the intracellular C-terminal tail and its binding partners.
T876ins, F881L, R886W, and R886P for
FHH/NSHPT and S895del, del920–970,
mutations on partner proteins, etc.
Thakker, 2004; Kemp et al., 2009; Stepanchick
et al., 2010; Grant et al., 2011; Arulpragasam
et al., 2012; Chakravarti et al., 2012; Davey et al.,
2012; Breitwieser, 2013; Nesbit et al., 2013
investigated the effect of FHH Ca2+ binding site 1 mutations,
such as Y218S (Pearce et al., 1996) and E297K (Bai et al.,
1999), both of which led to a loss-of-function with an increase
in EC50 for Ca2+ in terms of intracellular Ca2+ mobilization.
Additionally, E297K also decreases inositol-1-phosphate (IP1)
accumulation, but does not change CaSR cell expression levels as
compared to the wild-type (WT) (Bai et al., 1999). ADHmutation
E297D, as well as FHH mutation E297K, were analyzed by Silve
et al. for IP1 accumulation and expression levels (Silve et al.,
2005). Again, they saw no change in cell expression compared to
theWT, but they did see an activation shift for E297D, as the EC50
for Ca2+ induced IP stimulation changed from the WT EC50 of
4.30 ± 0.20 to 2.70 ± 0.30 mM, and a loss-of-function shift in
EC50 for E297K (Silve et al., 2005).
Additionally, mutations in residues neighboring the binding
site also show the same trend in an altered EC50 and
cooperativity but with no apparent effect on cell surface
expression or trafficking, such as the FHH/NSHPT mutations
S171N, R227Q, R227L, S296N, F351V, W352X, C395R, G397R,
the ADH mutations E191K, E241K, Q245R, and cancer-
associated mutations, S169F and S171G. Mutations on these
binding site residues or their neighboring residues would have
major effects on either direct binding or conformational direction
of the binding site residues, respectively. Pearce et al. looked at
two such mutants R227L (NSHPT) and E191K (ADH) (Pearce
et al., 1996). R227L increased EC50 for extracellular Ca2+ induced
intracellular Ca2+ response to 9.3mM compared to the WT
4.0mM, while the E191K mutant decreased EC50 for [Ca2+]o
from the WT 3.7 to 2.8mM. Western blot analysis showed that
compared to WT there was no increase or loss in expression
(Pearce et al., 1996). Thus, concluding that binding site residues,
and their immediate bordering residues, significantly alter the
charge or conformation of the binding pocket therefore altering
functionality into a gain-of or loss-of-function mutation with a
major effect on protein expression, translation, and/or trafficking.
The second type of disease mutations, type II, disrupts
molecular connectivity embedded into the hinge region of
the ECD (Figures 3, 5). Mutations at the particular region
of the N-terminal VFT domain produce either receptor
inactivation (L173P, P221Q) or activation (L173F, P221L)
related to hypercalcemic or hypocalcemic disorders. We have
shown that both L173P and P221Q markedly impair the
functional positive cooperativity of the CaSR as reflected by
Ca2+–induced intracellular Ca2+ oscillations, IP1 accumulation
and extracellular signal-regulated kinases (ERK1/2) activity. In
contrast, L173F and P221L show enhanced responsiveness of
these three functional readouts to [Ca2+]o change. Further
analysis of the dynamics of the VFT domain mutants using
computational simulation studies supports disruption in the
correlated motions in the loss-of-function CaSR mutants,
while these motions are enhanced in the gain-of-function
mutants. WT CaSR was modulated by L-Phe in a heterotropic
positively cooperative way, achieving an EC50 for Ca2+ induced
intracellular responses similar to those of the two activating
mutations. The response of the inactivating P221Q mutant to
Ca2+ was partially rescued by L-Phe, illustrating the capacity
of the L-Phe binding site to enhance the positive homotropic
cooperativity of CaSR. L-Phe had no effect on the other
inactivating mutant. Moreover, our results carried out both
in silico and within intact cells indicate that residue Leu173,
which is adjacent to residues that are part of the L-Phe-binding
pocket, exhibited impaired heterotropic cooperativity in the
presence of L-Phe. Thus, P221 and L173 are important for the
positive homo—and heterotropic cooperative regulation elicited
by agonist binding.
The third type of mutations, type III, directly affect CaSR
protein surface expression level which, in turn, alters potency
or cooperativity. Apparent functional cooperativity and the EC50
for extracellular Ca2+ elicited intracellular response of the CaSR
are also determined by the receptor expression level at the
plasma membrane (Christopoulos and Kenakin, 2002; Casadó
et al., 2007; Huang Y. et al., 2007). Like many other membrane
proteins, CaSR’s surface expression level is determined by the
rate of internalization and folding in the endoplasmic reticulum
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(ER) and Golgi, and membrane insertion. The CaSR protein
is synthesized in the ER and is trafficked intracellularly in the
ER and Golgi complex as it undergoes translations in the ER
and post-translational modifications before shuttling to the cell
surface. Interruptions in this trafficking from translation to cell
surface expression, such as those from disease mutations, can
lead to loss-of or gain-of-function CaSR on the cell surface,
CaSR that is retained in the ER or Golgi, or degraded altogether.
Breitwieser’s group investigated how these disease mutations
affect trafficking as a whole. They identified several classes
of mutations, spanning the whole CaSR length, which they
categorized based on their ability to traffic to the cell surface and
to have their function rescued by the positive allostericmodulator
NPS R-568. Class Ib mutations (Q27R, P39A, R66C, G143E,
L174R, G549R, C582Y, R638L, S657Y, G670E, P748R, G778D,
L849P) interrupt trafficking so substantially that the CaSR is not
able to leave the ER, while Class Ia mutations (E297K, C395R,
and A804D) similarly remain in the Golgi complex. All Class
I mutations fail to traffic to the cell surface. Class II mutations
still allows CaSR to reach the cell surface and their function
either can be enhanced by NPS R-568 (Class IIa: P55L, R62M,
S137P, R185Q, D215R, R227Q, G553R, L650P, R680C, V689M,
R795W, V817I) or not (Class IIb: L159P and P798T) (Huang
and Breitwieser, 2007; White et al., 2009). Consistent with these
observations, Leach et al. reported that FHH mutations S657Y,
G670R, G670E, R680H, R680C, M734R, G778D, and V817I
significantly decrease cell surface expression compared to the
WT; while ADH mutations F821L, V836L, and A843E increase
cell surface expression, although the ADH mutation F832S did
lead to a 45% decrease in surface expression (Leach et al., 2013).
The 14 cysteines found in the ECD and the cys-rich domain
were also found to affect CaSR function and cell surface
expression (Bai et al., 1998a; Fan et al., 1998; Zhang et al.,
2001). Of these 14 cysteines, 9 have disease mutations associated
with them producing ADH, FHH, and various carcinomas.
C129S and C131S, the cysteines thought to participate in the
homodimerization of CaSR through disulfide bond formation,
only led to a decrease of expression to 88 and 97%, respectively,
compared to WT CaSR. Whereas, C60S led to a decrease
in expression by half, and all other Cys mutations linked to
disease led to a decrease to lower than 28% or undetectable
levels (Fan et al., 1998). It is clear that the disruption of
disulfide formation as well as trafficking have profound effects on
functional cooperativity via alterations in both the Hill number
and the concentration of active form on the plasma surface.
The fourth mutational effect, type IV, alters CaSR interactions
with trafficking and stabilization partners leading to a change
in surface expression that further influences CaSR signaling as
well as functional cooperativity. Breitwieser et al. have concluded
that agonist-driven insertional signaling (ADIS) contributed to
the hallmarks of CaSR signaling, including the high degree
of cooperativity and the lack of functional desensitization.
Additionally, they have shown that the life cycle of the CaSR
controls the cellular abundance of CaSR, suggesting an intimate
link between trafficking and signaling (Breitwieser, 2012, 2013).
As shown in Figure 5 and Table 2, a large number of proteins
have been reported to interact at the C-terminal tail, the protein
interaction sensitive zone, of the CaSR (Hebert and Brown,
1995; Chakravarti et al., 2012; Brown, 2013). Interactions of
these proteins may be important for both CaSR signaling and
functional cooperativity. Among these proteins, E3 ubiquitin
ligase, dorfin is linked to ubiquitination and degradation of CaSR
via binding to C-terminal amino acids 880–968 (Huang et al.,
2006) and/or the C-terminal amino acids 920–970 (Zhuang et al.,
2012). Zhang et al. investigated the effect of lysosomal mediated
degradation of CaSRC-terminus and found that loss of the region
920–970 led to the highest cell expression level and decrease in
degradation (Zhuang et al., 2012). Several insertion and deletion
mutations in these regions of the C-terminus of CaSR lead to
ADH, resulting in reduced degradation and, therefore, over-
expression at the cell surface. Additionally, we have reported that
the surface expression of CaSR is largely influenced by interaction
of calmodulin (CaM) at residues 871–898 at the C-terminal tail of
CaSR. Interestingly, multiple disease mutations, such as T876ins,
F881L, R886W, and R886P for FHH/NSHPT and S895del for
ADH reside at this CaM binding region (Huang et al., 2010).
CaM has been reported to bind both the immature and mature
forms of CaSR, which suggests its role in modulating anterograde
trafficking (Bai et al., 1998b). We have shown that deletion of the
CaM binding region significantly abolishes/reduces functional
cooperativity of calcium oscillations. Therefore, CaM binding
stabilizes the receptor on the cell membrane and thus increases
potency of its functional activity (Huang et al., 2010). It is worth
pointing out that this region also is involved in phosphorylation
and biased signaling (Davey et al., 2012; Leach et al., 2012).
Moreover, protein 14-3-3 was reported to interact with the
arginine-rich domain of CaSR (890RRxxxxRKR898), which may
lead to the retention of CaSR in the ER (Stepanchick et al., 2010;
Grant et al., 2011; Arulpragasam et al., 2012). CaSR associated
disorders can also be caused by different mechanisms other than
direct mutations on the receptor itself. Recent studies by Nesbit
et al. and Rogers et al. revealed that disorders with FHH or ADH
phenotype can be associated with mutations on partner proteins
associated with CaSR-mediated signaling, for instance the loss-
of-function mutations of the sigma subunit of adaptor protein-
2 (AP2) and mutations on G-protein subunit-α11 (GNA11),
(Nesbit et al., 2013; Rogers et al., 2014). Moreover, antibodies
against the CaSR can also regulate the function of the receptor
(Thakker, 2004; Kemp et al., 2009, 2010).
ADDITIONAL MECHANISMS TO ALTER
THE FUNCTIONAL ACTIVITY OF CASR
There are several possible reasons why a single CaSR could
play a major role in various organisms, organs and tissue types
at different physiological environments. First, besides Ca2+,
other divalent cations such as Mg2+, Ba2+, Mn2+, Ni2+, Sr2+
(Thomsen et al., 2012), and trivalent cations La3+ and Gd3+ can
also interact at similar reported calcium binding sites, and/or in
their local vicinity, via altered electrostatic interactions of the
protein. In general, the higher the positive charge density, the
higher the potency as CaSR agonists. The CaSR has a relatively
low affinity for Mg2+ with an EC50 at about 10mM as measured
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TABLE 2 | The calcium-sensing receptor interacting proteins.
Protein Assay used Function CaSR domain References
AMSH Y2H, GST Trafficking/de-Ub enzyme C-terminal Herrera-Vigenor et al., 2006
β-Arrestin Functional Trafficking/signaling Unknown Lorenz et al., 2007
Caveolin Co-IP Structural/scaffolding/
trafficking/signaling
Intracellular loop 1 and 3 Kifor et al., 1998, 2003; Sun and
Murphy, 2010; Breitwieser, 2013
E3 Ub ligase Y2H, IP, functional Trafficking C-terminal Huang et al., 2006
Filamin Y2H, Co-IP, GST, functional Structural/scaffolding/trafficking C-terminal Awata et al., 2001; Hjälm et al., 2001;
Pi et al., 2002
GRK-2 Functional Signaling ICD Lorenz et al., 2007
GRK-4 Functional Signaling ICD Lorenz et al., 2007
Kir4.1 Y2H, Co-IP, functional K channel C-terminal Huang C. et al., 2007
Kir4.2 Y2H, Co-IP, functional K channel C-terminal Huang C. et al., 2007
PI-4-Kinase Co-IP, Signaling Unknown Huang et al., 2002
PKC Functional Signaling C-terminal Lorenz et al., 2007
RAMP1 Co-IP, functional Structural/trafficking ECD and 7TM Bouschet et al., 2005
RAMP3 Co-IP, functional Structural/trafficking ECD and 7TM Bouschet et al., 2005
RGS proteins Functional Signaling Unknown Huang et al., 2002, 2004
Rho Co-IP Signaling Unknown Huang et al., 2002
14-3-3 Yeast two-hybrid screen, CaSR
tail pull-down studies, Co-IP
Trafficking, expression,
signaling
Proximal membrane region,
CaSR C-terminal tail
Grant et al., 2011; Arulpragasam
et al., 2012
CaM GST, Co-IP, functional Signaling/stabilize C-terminal Huang et al., 2010
P24A Co-IP Stabilize/ trafficking C-terminal Stepanchick and Breitwieser, 2010
Sar1 Functional Trafficking ECD Zhuang et al., 2010
Rab1, Rab7, Rab 11a Functional, RNAi Trafficking/signaling Possible ECD Zerial and McBride, 2001; Grosshans
et al., 2006
Dorfin Co-IP, functional Trafficking Intracellular loop, C-terminal Huang et al., 2006
Integrins Co-IP, proteomic analysis,
co-localization, functional
Cell migration and adhesion
in cancer cells, trafficking,
signaling
Unknown Tharmalingam et al., 2011
for ligand induced current in oocytes, whereas there has been
a reported EC50 of 3mM for Ca2+ in the same assay (Brown
et al., 1993). Mg2+ also has only half the maximal capacity for
the production of inositol phosphate and arachidonic acid when
stimulated by Ca2+ in CHO cells transiently expressing rat CaSR
(Ruat et al., 1996). Consistently, CaSR transiently expressed in
HEK293 cells has EC50s for intracellular calcium responses of
15–20 and 3–5mM for Mg2+ and Ca2+ under physiological
conditions, respectively (Bai et al., 1996; Nearing et al., 2002).
CaSR ligands are also important for therapeutics, for example,
Sr2+ (as a ranelate salt) has been shown to be effective for
the treatment of osteoporosis (Kendler et al., 2009). CaSR has
also been seen to respond to binding ligands (e.g., Ca2+, Mg2+,
L-Phe, etc.) on a pH dependent manner where slightly lower
extracellular pH of 7.2 inhibits the binding of the ligand to CaSR,
and a higher pH of 7.6 favors the binding process (Campion et al.,
2015).
Second, various classes of agonists, antagonists and drugs can
also regulate the activation of CaSR via the ECD. The established
homotropic cooperativity and heterotropic co-activation model
of CaSR can also explain the regulatory action on CaSR.
Three basic peptides including poly-arginine, protamine, and
poly-lysine exhibited a dose-dependent inhibition of dopamine-
stimulated cAMP accumulation in dispersed bovine parathyroid
cells with EC50 values at micromolar or sub-micromolar
concentrations (Brown et al., 1991). Studies from Quinn et al.
demonstrated alteration of several cellular parameters including
[Ca2+]i change, IP production, and the activity of a nonselective
cation channel via polyamines. The potency of polyamines was
directly proportional to number of positive charges with the
order of spermine > spermidine > > putrescine (Quinn et al.,
1997). Glutathione and its γ-glutamyl peptides also allosterically
modulate the CaSR at a site that appears to be similar to the
L-amino acids binding site but with >100-fold higher apparent
affinity (Conigrave et al., 2000; Wang et al., 2006; Broadhead
et al., 2011). The EC50 values for GSH and the oxidized
form glutathione disulfide (GSSG), to induce intracellular Ca2+
mobilization, were in the range of sub-micromolar (0.08 and 0.33
µM, respectively) (Wang et al., 2006). In 2006, using [Ca2+]i
mobilization, PTH secretion, as well as intracellular cAMP
inhibition, Broadhead et al. showed γ-glutamyl-tripeptides (γ-
Glu-Cys-Gly, S-methylglutathione and S-propylglutathione, and
dipeptides γ-Glu-Ala and γ-Glu-Cys) to be positive allosteric
modulators of CaSR. They also found that the double mutant
T145A/S170T had an impaired response to these peptides,
indicating a potential peptide binding site at the extracellular
domain of CaSR (Broadhead et al., 2011). Recently, a peptide
drug AMG 416 has been shown to act as an agonist of the
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CaSR and is undergoing clinical trials (Walter et al., 2013).
Interestingly, the action of AMG 416 is also modeled to be at
the hinge region of the Phe-Site1 calcium binding site (Alexander
et al., 2015). Mutations on Cys482 at the hinge region lead
to impaired peptide activity in both pig and human CaSR
(Alexander et al., 2015).
Third, calcium sensitivity could be related with the difference
in CaSR sequence observed in various species. In mammals,
CaSRs were detected in multiple organ systems besides
parathyroid glands (e.g., kidneys, colon, skin, parathyroid,
stomach, vascular, bone, etc.), participating in various functions,
such as Ca2+ and fluid reabsorption, acid secretion, osteoblast
and keratinocyte differentiation, etc. (Tfelt-Hansen and Brown,
2005; Alfadda et al., 2014). The CaSR sequences among major
clades exhibit few differences both at the ECD and ICD. The
length of the ICD varies greatly among the clades (Herberger and
Loretz, 2013). Intriguingly, the sequence of the putative calcium
binding sites, especially the Site 1 within the ECD thought to be
the main Ca2+-binding domain, is relatively conserved among
vertebrates (Huang et al., 2009). On the other hand, residues in
the other predicted Ca2+-binding sites differ substantially, which
may be an effective way to adjust CaSR sensitivity to a specific
physiological environment, i.e., with varying Ca2+, Mg2+, or
pH, and also for evolution. For example, CaSR is present in
different organs of fish, suggesting it might play a crucial role
in sensing the changes in the salinity in surrounding water with
calcium concentrations changes from 10mM in sea water to
0.07–2.0mM in freshwater. The presence of many alternatively
spliced forms of the human CaSR could imply an impact of these
altered sequences on the CaSR’s Ca2+ sensitivity (Oda et al., 1998,
2000).
Fourth, Ca2+ signaling could be modulated through the
formation of CaSR hetero-dimers with other GPCRs or higher
order oligomers with non GPCR chaperones in tissues other
than parathyroid. Gama et al. showed co-localization of the
CaSR and mGluR1α in hippocampal and cerebellar neurons by
immunoprecipitation of CaSR from bovine brain. The CaSR
became sensitive to glutamate triggering internalization and
exhibited altered trafficking via reported hetero-dimerization
with GABAB receptors (Gama et al., 2001). Thus, it was
speculated that the CaSR would respond to Ca2+ concentration
within the synaptic cleft at various levels of synaptic activity.
Recent work by Kim et al. revealed that CaSR forms a
heteromeric complex with the inhibitory type B γ-aminobutyric
acid receptor 1 (GABABR1) in hippocampal neurons (Kim et al.,
2011). This study demonstrates a novel receptor interaction,
which contributes to ischemic neuron death through CaSR
upregulation and GABABR1 downregulation, and feasibility of
neuroprotection by concurrently targeting these two receptors.
It is also a new way to tailor functional cooperativity and
specificity.
CONCLUSION AND PERSPECTIVE
Recently, the crystal structure of extracellular domain has
been first solved by our group. We reported the first
CaSR crystal structure with multiple Mg2+ binding sites
(Zhang et al., 2016). Consistent to our modeled structure
reported earlier, the determined X-ray structure of the ECD
shares the same fold of the mGluRs with the VFT motif.
Unexpectedly, we also identified a tryptophan derivative L-
1,2,3,4-tetrahydronorharman-3-carboxylic acid (TNCA) at the
hinge region between the two subdomains where orthosteric
ligand binding is thought to occur. We further demonstrated that
TNCA binds to CaSR at unusually high affinity and potentiates
CaSR activity with Ca2+ and Mg2+ (Zhang et al., 2016). Geng
and colleagues subsequently reported X-ray structures of CaSR
ECD in both apo form and the Ca2+ binding form. Similar
as proposed in earlier studies, CaSR active form contained
multiple binding sites for Ca2+. Additional Ca2+ bound sites
and PO3−4 binding sites were reported. They also showed that
L-Trp bound to the orthosteric agonist-binding site in CaSR
active form (Geng et al., 2016). These advances and various
pioneer studies since the discovery of CaSR in understanding
the cooperative extracellular Ca2+ signaling mediated through
CaSR have uncovered important structural and functional
characteristics about this receptor. Family cGPCRs all sense
extracellular calcium with differing degrees and also exhibit
sensitivity to either amino acids, neurotransmitters, or related
ligands. The discovered co-activation by calcium and amino
acids of CaSR is likely to have a broad impact for the
regulation of cGPCRs. However, many questions about CaSR
are still unanswered. Though accelerated elucidation of cGPCR
structures have been accomplished, the unavailability of the
full CaSR structure and largely “invisible loop residues” in the
determined structure of cGPCRs limit the next step forward on
understanding of molecular mechanism of CaSR. Thus, high
resolution structures of CaSR with various forms of agonists
and antagonists are essential to gain a better understanding
of the underlying mechanism in CaSR regulated physiological
functions as well as pathological activities. Equal importance
should be directed at studies designed to probe the functional
cooperativity of CaSR as it plays a pivotal role in controlling
the receptor response within a narrow fluctuation of metal
concentration. Family cGPCRs are highly relevant for drug
design and have tremendous potential as therapeutic targets
because cGPCRs play vital roles in neurotransmitter release
and Ca2+ homeostasis. The aforementioned results, along with
further determination of the structure of CaSR, will provide great
insights into the molecular basis of the structure and function of
CaSR and shed new light on other cGPCRs in health and disease
states. Thus, further uncovering of the structural and functional
mysteries of CaSR could aid the development of novel receptor-
based therapeutics to use in the treatment of many different
diseases.
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